Mechanisms that drive addiction to sugar rich foods are a major driving factor in the pathogenesis of obesity, which has become one of the most significant health care burdens. The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a multimodal effect influencing many pathways related to aging including calorie restriction. Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower food intake.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of California, San Francisco

NCT06465602 / RecruitingPhase 2IIT

Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls: a Pilot Randomized Clinical Trial

Falls are unplanned events resulting in contact with a lower surface. They are common in older adults, affecting one in three individuals over 65 years old. They have serious consequences, ranging from physical injuries (fractures, traumatic brain injury) to psychological repercussions. Physical training focused on muscle strength, balance, and gait has consistently been shown to prevent falls. However, there are significant challenges in its implementation, such as the need for trained personnel and long intervention times, which are associated with high costs. Therefore, developing strategies to improve the efficiency of physical training programs in older adults is mandatory. The reduced response to physical training in older adults compared to younger individuals is a well-documented phenomenon, reflecting physiological changes associated with aging.
Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme for cells, mediating energy metabolism and participating in crucial processes such as DNA repair, mitochondrial function, and cell death. As we age, NAD+ levels decrease in various tissues (including the brain and muscle), contributing to the development of aging phenotypes and associated pathologies. Preclinical evidence suggests that increasing NAD+ levels reduces the appearance of aging phenotypes. During physical activity, cellular metabolic pathways that increase the demand for NAD+ to support energy production in mitochondria are activated. This increase in demand is associated with the upregulation of key enzymes involved in NAD+ degradation promoted by exercise. Considering the decrease in cellular levels of this coenzyme associated with aging, it can be hypothesized that NAD+ deficiency may play a significant role in the reduced response of older adults to training programs. Nicotinamide, a water-soluble form of vitamin B3 currently considered a nutritional supplement, is a fundamental precursor for NAD+ synthesis, capable of raising cellular levels of it. It has already been used in clinical practice in the treatment of certain endocrinological and dermatological conditions. This study aims to determine through a randomized clinical trial whether nicotinamide supplementation improves physical performance in older adults at risk of falls undergoing a physical training program.

Start Date21 May 2024

Sponsor / Collaborator

University of Chile

NCT06331390 / RecruitingNot ApplicableIIT

Randomized Controlled Trial of Niacinamide Cosmetic Product Efficacy in Model of Irritant Contact Dermatitis

Testing the effectiveness and safety of cosmetics with niacinamide in irritant contact dermatitis: A Randomised, Controlled Trial will be conducted at USSM. Healthy volunteers will be included (at least 25) and test sites are forearms. Sodium lauryl sulphate will be used to induce contact dermatitis and participants will be measured for 7 days

Start Date01 Apr 2024

Sponsor / Collaborator-

100 Clinical Results associated with Nicotinamide

100 Translational Medicine associated with Nicotinamide

100 Patents (Medical) associated with Nicotinamide

5,556

Literatures (Medical) associated with Nicotinamide

01 Feb 2024·Drug metabolism and pharmacokinetics

Improvement of transdermal absorption rate by nonthermal biocompatible atmospheric pressure plasma

Article

Author: Rana, Juie Nahushkumar ; Han, Ihn ; Kim, Byoung-Choul ; Choi, Eun Ha

Nonthermal biocompatible plasma (NBP) is a promising option for improving medication absorption into the human skin. Currently, most plasma devices for cosmetics employ a floating-electrode plasma source for treating the skin. Human skin serves as the ground electrode in the floating-electrode plasma discharge, and discharge occurs between the skin and electrodes of the device. In this in vitro study, we aimed to evaluate the effect of NBP on the skin permeation of niacinamide. We have quantified the transdermal absorption rates of niacinamide in both untreated skin and skin treated with NBP for a duration of 10 s. The absorption of niacinamide for both without and with NBP treatment was observed until 12 h incubation time. Without plasma treatment, the human skin exhibited stable and low transdermal absorption of niacinamide up to 12 h. However, the NBP treatment significantly increased the transdermal absorption of niacinamide from 0.5 h to 6 h and continuously increased skin penetration over a duration of more than 12 h incubation period. The obtained results suggest that NBP-treated human skin showed a 60-fold higher penetration rate than non-treated skin. The increased penetration rate of niacinamide can be mainly attributed to plasmaporation subsequent to NBP treatment. The findings of this study demonstrate that NBP treatment results in remarkable skin permeability, making it a promising candidate for both cosmetic and pharmaceutical delivery applications.

01 May 2024·Journal of cosmetic dermatology

Efficacy of ceramides and niacinamide‐containing moisturizer versus hydrophilic cream in combination with topical anti‐acne treatment in mild to moderate acne vulgaris: A split face, double‐blinded, randomized controlled trial

Article

Author: Tempark, Therdpong ; Shem, Andrew ; Lueangarun, Suparuj

Abstract:

Introduction:

Topical therapy is the mainstay treatment of acne, and topical retinoids such as tretinoin, tazarotene, and adapalene are recommended as the first‐line therapy for mild to moderate acne. However, the cutaneous irritations may occur, and the dermocosmetics are recommended to prevent side effects of anti‐acne drugs and adhere to treatment. Thus, this study aims to compare the efficacy and tolerability of ceramides and niacinamide‐containing moisturizer (CCM) versus hydrophilic cream in combination with topical anti‐acne treatment in mild to moderate acne vulgaris.

Methods:

This was an 8‐week, randomized, double‐blinded, split face study in 40 patients assigned for topical anti‐acne medications (5% benzoyl peroxide and 0.1% adapalene gel), then randomly applied CCM or hydrophilic cream. All patients were followed at week 0, 2, 4, and 8 for acne improvement, adverse reactions, biometric, and biophysical evaluation.

Results:

CCM could significantly improve the non‐inflammatory, inflammatory, and total acne lesions compared with hydrophilic cream after week 8 of treatment. Interestingly, there was an improvement of global worst score, hemoglobin index, melanin index, TEWL, skin hydration, sebum production, and skin surface pH, with no statistically significant differences between the two treatments. No serious side effects from clinical application of CCM and hydrophilic cream in mild to moderate acne vulgaris patients.

Conclusion:

Ceramide and niacinamide‐containing moisturizer in combination with anti‐acne medication can significantly improve acne lesions and decrease cutaneous irritations toward a satisfactory treatment outcome of mild to moderate acne vulgaris.

01 Feb 2024·Journal of cosmetic dermatology

The effects of supramolecular nicotinamide combined with supramolecular salicylic acid on chloasma

Article

Author: Cheng, Yao ; You, Yan ; Zhang, Liang

Abstract:

Objective:

To observe the efficacy and safety of supramolecular salicylic acid monotherapy and supramolecular nicotinamide in the treatment of chloasma.

Methods:

A total of 28 female patients with chloasma diagnosed in the dermatology outpatient department of our hospital were randomly divided into an experimental group and a control group, with 14 cases in each group. All patients were treated with 30% supramolecular salicylic acid every 2 weeks, for a total of 8 treatments. The experimental group was treated with 10% supramolecular nicotinamide once in the morning and once in the evening, and the control group was a blank control. Before each exfoliation treatment, subjects were photographed with a VISIA skin detector, and skin image analysis and modified melasma area and severity index (MASI) score were performed.

Results:

According to the MMASI decrease rate (%) before and after treatment, the effective rate of the experimental group was 64.29%, and the effective rate of the control group was 14.29%. The results of the GriffithS10 and VISIA were improved. During the whole treatment, there was one mild adverse reaction in both groups.

Conclusion:

Salicylic acid stripping combined with nicotinamide in the treatment of chloasma is safe and effective, can improve skin conditions, and can be widely applied in clinical practice.

News (Medical) associated with Nicotinamide

14 Jun 2024

·www.sciencedaily.com

Scientists solve decades long mystery of NLRC5 sensor function in cell death

A new study identifies NLRC5 as an innate immune sensor that plays a crucial role in PANoptotic cell death -- making it a key therapeutic target. The innate immune system is responsible for protecting the human body from threats that could cause disease or infection. The system relies on innate immune sensors to detect and transmit signals about these threats. One of the key innate immune strategies to respond to threats is through cell death. New research from St. Jude Children's Research Hospital discovered that NLRC5 plays a previously unknown role as an innate immune sensor, triggering cell death. The findings, published in Cell, show how NLRC5 drives PANoptosis, a prominent type of inflammatory cell death. This understanding has implications for the development of therapeutics that target NLRC5 for the treatment of infections, inflammatory diseases and aging. Depending on the threat, innate immune sensors can assemble complexes such as inflammasomes or PANoptosomes. The inflammasome can be thought of like an emergency broadcast system that is activated quickly, while the PANoptosome is more like an emergency response unit that generally integrates more signals and components to respond to the threat. How innate immune sensors work -- what triggers them to act -- has been a mystery, which researchers have been chipping away at for decades. Nucleotide-binding oligomerization domain-like receptors (NLRs) are a large family of important molecules involved in inflammatory signaling. They are generally thought to function as innate immune sensors that detect threats. However, the specific roles of several NLRs in sensing are not yet understood. Scientists at St. Jude conducted a large screen, testing a specific NLR, NLRC5, to see what threats activate it. Through their efforts, they discovered that depletion of nicotinamide adenine dinucleotide (NAD), a molecule essential in energy production, triggers NLRC5-mediated cell death through PANoptosis. "One of the biggest questions in the fields of immunology and innate immunity is what the various members of the NLR family are sensing, and what their functions are," said corresponding author Thirumala-Devi Kanneganti, PhD, St. Jude Department of Immunology vice chair. "NLRC5 was an enigmatic molecule, but now we have the answer -- it is acting as an innate immune sensor and cell death regulator, driving inflammatory cell death, PANoptosis, by forming a complex." Identifying the NLRC5 trigger Scientists in the Kanneganti lab conducted a rigorous screen to get to the bottom of what threats trigger NLRC5. This included looking at pathogens such as bacteria and viruses, as well as pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) that can be released by or mimic an infection or the cause of an injury or illness, as well as other danger signals such as cytokines (immune signaling molecules). The researchers also looked at heme, the component of hemoglobin responsible for carrying oxygen. Infections or disease can cause red blood cells to rupture in a process called hemolysis. This releases hemoglobin into the bloodstream. When hemoglobin breaks down into its components, it releases free heme, which is known to cause significant inflammation and organ damage. The researchers tested many different combinations of pathogens, PAMPs and DAMPs to see if NLRC5 was required for a response. "Among all the combinations we tested, we identified that the combination of heme plus PAMPs or cytokines specifically induces NLRC5-dependent inflammatory cell death, PANoptosis," said co-first author Balamurugan Sundaram, PhD, St. Jude Department of Immunology. "Our results showed for the first time that NLRC5 is central to responses to hemolysis, which can occur during infections, inflammatory diseases and cancers." Energy depletion triggers NLRC5 function Upon identifying the heme-containing PAMP, DAMP and cytokine combinations that trigger NLRC5-dependent inflammatory cell death, the researchers further investigated how NLRC5 is regulated. They found that NAD levels drive NLRC5 protein expression. If NAD is depleted, that sounds an alarm that there is a threat the immune system should recognize. The researchers found that depletion of NAD is sensed by NLRC5, triggering PANoptosis. "By supplementing with the NAD precursor, nicotinamide, we reduced NLRC5 protein expression and PANoptosis," said co-first author Nagakannan Pandian, PhD, St. Jude Department of Immunology. "Therapeutically, nicotinamide has been widely studied as a nutrient supplement, and our findings suggest it could be helpful in treating inflammatory diseases." The researchers also discovered that NLRC5 is in an NLR network with NLRP12, which come together with other cell death molecules and form an NLRC5-PANoptosome complex that triggers inflammatory cell death. The finding builds on previous research by the Kanneganti lab showcasing the role of NLRP12 in PANoptosis. A promising target for therapeutic development NLRs are associated with diseases related to infection, inflammation, cancers and aging. This makes them intriguing targets for the development of novel therapeutics. The work of the Kanneganti lab shows that deleting Nlrc5 can provide protection against inflammatory cell death through PANoptosis and prevent disease pathology in hemolytic and inflammatory disease models, making NLRC5 an exciting therapeutic prospect. "The fundamental knowledge that we have gained into how innate immune sensing works can be translated to numerous diseases and conditions," Kanneganti said. "Aging, infectious disease, inflammatory disorders -- things for which there are no targeted therapies, this could be an option." Authors and funding The study's other authors are Emily Alonzo, Department of Research and Development at Cell Signaling Technology; and Hee Jin Kim, Hadia Abdelaal, Omkar Indari, Roman Sarkar, Rebecca Tweedell, Jonathan Klein, Shondra Pruett-Miller and Peter Vogel, all of St. Jude, and Raghvendra Mall, formerly of St. Jude now of the Technology Innovation Institute, Abu Dhabi. The study was supported by grants from the National Institutes of Health (AI101935, AI124346, AI160179, AR056296 and CA253095) and ALSAC, the fundraising and awareness organization of St. Jude.

17 May 2024

·www.prnewswire.com

GV Announces Cooperation with Top 500 Company in China

TORONTO, May 17, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced the Company and Red Sun Group, a top 500 company in China, are collaborating to jointly invest in establishing a life sciences industry conglomerate in Toronto. This initiative aims to contribute globally to achieving the mission of "health, happiness, beauty, and longevity" for humanity, making it a top contributor in preventive medicine and natural medicine. Visionary Group and Red Sun Group, a top 500 company in China, are collaborating to jointly invest in establishing a life sciences industry conglomerate in Toronto. This conglomerate aims to become the world's largest platform for nicotinamide (whitening) and anti-aging NMN (nicotinamide mononucleotide) industries. Leveraging Red Sun Group's globally leading nicotinamide and NMN raw material base and technological platform, Visionary Group plans to establish a complete industry chain business system from raw materials to functional foods, skincare products, functional animal health products, and future medical terminal products. These products serve global cosmetics, food manufacturing, animal products, pharmaceutical, and medical institutions, as well as end customers. Harvard University scientist David Sinclair confirms the life-extending effect of NMN Visionary Group cooperates with Red Sun Group, a Fortune 500 company in China, to establish a cooperation project of a life science industry group in Toronto, which has the core of the health care industry: 1. Biotechnology innovation and bio-patented technology: Red Sun Group has the world's leading nicotine and NMN raw material production and technology platforms, and can provide high-quality products through innovation, which is important for promoting the life science industry and related functionalities The development of food and health products is crucial. 2. Capabilities and conditions for high cross-border integration of the health industry chain: By establishing a complete industrial chain from raw materials to final products, we can not only enhance the competitiveness of high-quality products, but also fully control production costs and quality, thereby more effectively meeting global and global needs. Canada's vast market demand. 3. Accurate target market demand positioning and expansion: The group's products serve many fields such as cosmetics, food manufacturing, animal products, pharmaceuticals and medical institutions. Its diversified market positioning helps expand the target market and customer base to increase market share. 4. Global trends and health needs: Anti-aging and whitening products are in line with the current demand trends of global consumers, especially for customer groups who pursue healthy quality of life and appearance care. This can ensure the core value and continued sustainability of the products in the market need. 5. Transnational research and development (R&D): Companies invest in research and development of new products and technologies, which not only helps maintain product innovation and competitiveness, but is also a key factor in stabilizing and expanding market positions. 6. Sino-Canadian international cooperation: This kind of transnational cooperation is essential for strengthening international business relations and expanding global markets, and can also enhance the international image of corporate brands. 7. Sustainability contributes to human health and positive corporate social responsibility: Corporate behavior consistent with sustainable development increases the company's awareness of the environment and its investment in social responsibility, which helps enhance the corporate image and attract investors . Cross-border cooperation projects can bring high-growth opportunities driven by biotechnology innovation to participating group companies, and have the potential to shape the future global trends in related health industries. NMN Nicotinamide Mononucleotide Market Size and Forecast The nicotinamide mononucleotide market size is US$5 billion in 2023 and is expected to reach US$12.93 billion by 2031, with a compound annual growth rate from 2024 to 2031 of 9.1%. and play an important role in the market. Nicotinamide mononucleotide (NMN)'s potential health benefits and growing use in the anti-aging and longevity fields are driving the phenomenal growth of the market. Nicotinamide adenine dinucleotide (NMN) is the precursor of NAD+ and is essential for cellular energy synthesis and DNA repair processes. Research on the importance of NMN in supporting cellular resiliency and health continues, generating strong interest from customers looking for longevity solutions. Furthermore, the market for NMN supplements is growing and is expected to continue to grow in the foreseeable future due to factors such as the aging world population and people's desire for a better lifestyle. Nicotinamide mononucleotide (NMN) market is expanding owing to many important parameters. First, growing consumer awareness of NMN's possible anti-aging and life-extending effects is driving demand for NMN supplements. Secondly, more and more studies have demonstrated the function of NMN in DNA repair pathways and cellular energy metabolism, encouraging its use in the health and wellness industry. Thirdly, the market is growing as age-related diseases are becoming more common as the elderly population is seeking preventive healthcare measures. Additionally, endorsements from celebrities and medical professionals have further enhanced consumer confidence in NMN supplements, thereby driving market expansion. As the search for healthy aging solutions continues to heat up, there is still plenty of room for growth in the NMN market. Mechanism of Action of NMN Increased Nicotinamide Mononucleotide (NMN), a precursor to NAD, promotes axonal regeneration post-injury. NMN exhibits novel physiological functions in mammals, unveiling unexpected links between cancer chemotherapy strategies and axonal disease treatments. NMN has novel physiological functions in mammals and reveals unexpected connections between new strategies for cancer chemotherapy and the treatment of axonopathies . Reverse Aging: Harvard Scientist Dr. David Sinclair on NMN and Anti-Aging Supplements Dynamic of Nicotinamide Mononucleotide (NMN) Market Market Drivers: Rising consumer awareness of anti-aging benefits: Increasing consumer awareness of the potential anti-aging benefits of NMN is driving demand for NMN supplements. Extensive research supports NMN's health benefits: Extensive scientific research emphasizes NMN's role in cellular energy metabolism and DNA repair mechanisms, driving its adoption in the health and wellness sector. Increasing prevalence of age-related diseases: The increasing prevalence of age-related diseases, coupled with global population aging, is driving demand for preventive healthcare measures (including NMN supplements). Endorsement from healthcare professionals and celebrities: Endorsement and recommendations from healthcare professionals and celebrities are enhancing consumer confidence in NMN supplements, driving market growth. Market Challenges: Regulatory barriers and compliance issues: Regulatory barriers and compliance requirements related to the marketing and distribution of NMN supplements pose challenges for market entry and expansion. High production costs: High production costs associated with manufacturing NMN supplements (including purification and quality control processes) may affect pricing and profit margins. Limited clinical evidence: Despite promising research results, limited clinical evidence supporting the efficacy and safety of NMN supplements may hinder widespread adoption by consumers and healthcare professionals. Competition from alternative anti-aging solutions: Competition from alternative anti-aging solutions (such as other NAD+ precursors and dietary supplements) presents challenges for market penetration and differentiation. Market Trends: Focus on personalized nutrition: The trend towards personalized nutrition and health solutions is driving the development of customized NMN formulations tailored to individual health needs and preferences. Expansion of distribution channels: The expansion of distribution channels, including online platforms and specialty health stores, is widening access to NMN supplements, driving market growth. Product formulation innovation: Market participants are innovating new product formulations, such as NMN capsules, powders, and sublingual tablets, to enhance bioavailability and ease of consumption. Integration of NMN in beauty and cosmetics: The integration of NMN in beauty and cosmetic products, due to its anti-aging properties, reflects the growing trend towards holistic health and beauty solutions. The NMN market report compiles complex information targeting specific niche markets, providing an in-depth overview of specific industries or across different sectors. This comprehensive report combines quantitative and qualitative analysis, predicting trends from 2023 to 2031. It utilizes industry terminologies, key players, consumer behavior, and the national economic, political, and social landscape. The thorough segmentation of the report ensures a comprehensive analysis of the market from various perspectives. This detailed report delves into key areas, extensively examining market segmentation, market prospects, competitive landscapes, and company profiles. These sections provide detailed insights from different angles, considering factors such as end-use industries, product or service categorizations, and other relevant sub-segments aligned with current market conditions. This comprehensive analysis aids in optimizing ongoing marketing strategies. In the market outlook section, a deep analysis of market evolution is conducted, examining growth drivers, barriers, opportunities, and challenges. This involves a thorough exploration of the Porter's Five Forces framework, macroeconomic assessments, value chain reviews, and comprehensive pricing analysis—all of which actively shape current market dynamics and are expected to continue influencing the market during the forecast period. Internal market factors are elucidated through drivers and constraints, while external influences shaping the market are detailed through opportunities and challenges. Additionally, this section provides valuable insights into popular trends influencing emerging business ventures and investment opportunities. About Visionary Holdings Inc. Visionary Holdings Inc. headquartered in Toronto, Canada, a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China. The Company aims to provide access to secondary, college, undergraduate and graduate and vocational education to students in Canada through technological innovation so that more people can learn, grow and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the Company has been serving and will continue to serve both Canadian and international students. For more information, visit the Company's website at . Forward-Looking Statements All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "believes," "expects," "anticipates," "estimates," "intends," "would," "continue," "should," "may," or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC. For more information, please contact: Visionary Holdings Inc. Investor Relations Department [email protected] SOURCE Visionary Holdings Inc.

Oligonucleotide

09 Apr 2024

·www.prnewswire.com

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne

From the makers of BOTOX® Cosmetic, two new SkinMedica® acne products help address skin blemishes and can be combined with in-office DiamondGlow® IRVINE, Calif., April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica® by the makers of BOTOX® Cosmetic. The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin. The two products, along with the SkinMedica® Pore Purifying Pro-Infusion Serum, used in-office with DiamondGlow®, complete the protocol, providing acne sufferers a continuum of products to help address their skin concerns. "Acne is the most common skin concern in the US.1 It is also the primary reason patients schedule an office visit with their provider.2 For 25 years, SkinMedica® has been dedicated to perfecting scientifically proven skincare that yields visible results," said Jasson Gilmore, Senior Vice President, U.S. Aesthetics. "The formulations of the new products continue the legacy of promoting skin health and addressing key patient concerns like acne." In clinical studies, participants who used the SkinMedica® Acne Clarifying Treatment and Pore Purifying Gel Cleanser noticed clearer skin while reporting that the products did not dry their skin out. Additionally, clinical study participants noted the treatment regimen helped calm their skin.3 The SkinMedica® approach to addressing acne focuses on efficacy while respecting the skin barrier to help break the acne cycle by balancing sebum, soothing visible redness, and preserving the microbiome. "Navigating the challenges posed by acne can be difficult, and most acne products are effective at targeting acne but ignore the impact of the ingredients on the skin barrier," said Dr. Mona Gohara, board-certified dermatologist and associate clinical professor at Yale University. "My patients often find themselves in a bind when choosing acne products that treat acne but don't compromise the skin barrier. I am excited to offer my patients these new products from SkinMedica®, which focus on sebum regulation and barrier protection to create a desirable balance of low irritation with strong efficacy." The SkinMedica® Acne Clarifying Treatment is formulated with 2% encapsulated salicylic acid, which proactively guards against future breakouts. The product also includes ingredients like niacinamide and bakuchiol, which work together to reduce the appearance of discoloration and post-acne marks while refining pores and enhancing skin tone. With each application, this treatment becomes a shield, preserving the skin's natural barrier. MSRP $66. Complementing the Acne Clarifying Treatment is the SkinMedica® Pore Purifying Cleanser, which is infused with salicylic acid, a beta-hydroxy acid, to help remove impurities while a potent blend of antioxidants and soothing botanicals like aloe and chamomile caress the skin, leaving behind a soft and refreshed canvas. MSRP $46. The new SkinMedica® products are available for purchase at SkinMedica.com and through a network of licensed physicians and medically supervised spas. To experience the SkinMedica® Pore Purifying Pro-Infusion Serum for DiamondGlow®, find a provider by visiting DiamondGlow.com. For more information follow @SkinMedica on Instagram. About Allergan Aesthetics At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. DiamondGlow® Uses The DiamondGlow® device is a general dermabrasion device that gently removes the top layer of skin and delivers topical cosmetic serums onto the skin. DiamondGlow® Important Safety Information The DiamondGlow® treatment is not for everyone. You should not have a DiamondGlow® treatment if you have compromised skin quality. Tell your provider if you are pregnant or lactating, or if you have any medical conditions, including allergies, and if you are using topical medications on the area to be treated. Typical side effects include a scratchy, stinging sensation during the treatment and temporary tightness, redness or slight swelling after the treatment. Rare serious side effects may also occur and include severe skin irritation and allergic reactions. SkinMedica® Pro-Infusion Serums Disclaimer SkinMedica® Pro-Infusion Serums are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These products are not intended to be drugs that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA. Please talk to your provider for additional information. SkinMedica® Important Information Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA. SkinMedica® Acne Clarifying Treatment is an over-the-counter drug product which is formulated and marketed pursuant to FDA's governing regulations set forth at 21 CFR Part 333 Subpart D. For more information, please talk to your provider or visit SkinMedica.com and DiamondGlow.com. To report an adverse reaction, please call Allergan at 1-800-433-8871. BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES IMPORTANT SAFETY INFORMATION BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic: Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months. Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing. BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product. There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines. BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities. Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint. Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site. Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic. Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk). Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past. Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners. Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes. Approved Uses BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults. For more information refer to the Medication Guide or talk with your doctor. To report a side effect, please call Allergan at 1-800-678-1605. Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide. References: AAD () Kline. Prograde Skincare Report. 2022.(According to Kline's Physician-Dispensed Skin Care: US Perception and Satisfaction Survey 2022, physicians noted that acne was the most common skin condition that patients visit physician's office for, followed by fine lines/wrinkles, sagging skin, and pigmentation.) Data on file at SkinMedica ® SOURCE AbbVie

100 Deals associated with Nicotinamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00036	Nicotinamide	A11HA01	DB02701

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arrhythmias, Cardiac	CN	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Coronary Artery Disease	CN	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Myocarditis	CN	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Vitamin B Deficiency	CN	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1996
Pellagra	JP	Catalent Japan KK	27 Oct 1961
Acne Vulgaris	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 2	DE	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010
Hyperphosphatemia	Phase 2	DE	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03912220 (CTgov)	Phase 2	Small Fiber Neuropathy	45	Nicotinamide riboside (Nicotinamide Riboside)	lqrsptmihm(nqhxswvoob) = adoopdxhxm vtfwqndqke (aqrlflgogk, svljciwszh - rliuocwcdd) View more	-	06 Jun 2024
				Placebo Oral Tablet (Placebo)	lqrsptmihm(nqhxswvoob) = lqzoevrmiu vtfwqndqke (aqrlflgogk, wwjznyjfsl - deqjvbjfko) View more
NCT02416739 (Pubmed)	Phase 2	EGFR Mutation Lung Cancer EGFR mutations	110	Nicotinamide	xlbgzarbow(kwzymkjwqc) = rgdtjzbcfu wnucrdiydz (yxxvdkrstz, 10.4 - 18.3) View more	-	09 Apr 2024
				Placebo	xlbgzarbow(kwzymkjwqc) = pourwlabid wnucrdiydz (yxxvdkrstz, 9.0 - 13.2) View more
NCT02416739 (AACR2024) Manual	Phase 2	EGFR Mutation Lung Cancer EGFR Mutation	110	Nicotinamide+EGFR-TKIs	mwzkbovpxm(taoiaafrgk) = lnacgvkvej fcwnofotcn (iruqsoteuc, 10.4 ~ 18.3) View more	Positive	05 Apr 2024
				Placebo+EGFR-TKIs	mwzkbovpxm(taoiaafrgk) = kehtfqrcpb fcwnofotcn (iruqsoteuc, 9.0 ~ 13.2) View more
NCT03136705 (CTgov)	Phase 1	-	39	Lanthanum Carbonate+Nicotinamide (Lanthanum + Nicotinamide)	zaryqabhnx(xyjarqxfhc) = rbikjxwjiz tddhaegmqk (ssvybxflri, irojlxhxhj - turheeggvi) View more	-	23 Feb 2024
				Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo)	zaryqabhnx(xyjarqxfhc) = kbjgulxxbu tddhaegmqk (ssvybxflri, kchrzayzhn - hfojqmssyj) View more
NCT03061474 (CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	46	Nicotinamide (Nicotinamide)	wnkkcugzdb(lcxahujyca) = bzekbfaxsd ajtbdnkqnn (ilwdxsxedi, qivlarfgal - khvmwzvrrs) View more	-	17 Oct 2023
				Placebo Comparator (Placebo)	wnkkcugzdb(lcxahujyca) = erwrcwfbya ajtbdnkqnn (ilwdxsxedi, biqmbzzmbb - uavvlyukie) View more
WCD2023	Not Applicable	-	-	High broad spectrum sunscreen containing Nicotinamide and Panthenol	geojmpawjs(ttbmcmaoei) = xtymvgalzs wdtevbbijf (xeppdwxkff ) View more	Positive	03 Jul 2023
ACTRN12617000599370 (Pubmed \| Br Dent J)	Phase 3	Skin Neoplasms	158	Nicotinamide 500 mg	augdymuyul(rzwfbmbqix) = rojunhksmn anerskungk (stkxwopuxb )	Negative	02 Mar 2023
				Placebo	augdymuyul(rzwfbmbqix) = tmffxzbapo anerskungk (stkxwopuxb )
NCT03419364 (CTgov)	Phase 2	Pre-Eclampsia	23	nicotinamide (Nicotinamide - Pre-eclampsia)	ikcrakltjd(smrbqwnhfl) = kdwlwrgjpc pekazmrtag (kbfevxxifu, vozsufxyzb - dlxyjstram) View more	-	08 Sep 2022
				nicotinamide (Nicotinamide - Healthy Pregnant)	ikcrakltjd(smrbqwnhfl) = elsjmgxaqj pekazmrtag (kbfevxxifu, cmxvcfltsx - oleberwxeg) View more
NCT02416739 (WCLC2022)	Phase 2/3	EGFR-mutated non-small Cell Lung Cancer	110	Nicotinamide	ymsugwvkph(fohmcwhyhw) = idqwsqvcva jckeovqnuu (jrklbuxvsm ) View more	-	06 Aug 2022
				Placebo	ymsugwvkph(fohmcwhyhw) = swyqstzfrt jckeovqnuu (jrklbuxvsm ) View more
NCT02258074 (CTgov)	Phase 2	Chronic Kidney Diseases	205	Lanthanum Carbonate+Nicotinamide (Lanthanum Carbonate + Nicotinamide)	ysukfgpbxd(uiztvqtvku) = nmmaghzino szmtmlfona (ivbxsnfjsl, cjsquugxwp - ufrusszdzu) View more	-	30 Jul 2021
				Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo)	ysukfgpbxd(uiztvqtvku) = rmrcvqytot szmtmlfona (ivbxsnfjsl, mqoxmccayo - qqljjcopxx) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis